Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
SHR-1210 in previously treated advanced hepatocellular carcinoma
CTR20160871Phase 3Completed
- Sponsor
- Hengrui Therapeutics
- Start
- Nov 2016
- Modality
- Immune Checkpoint Inhibitors → Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
A Phase 3 trial of camrelizumab in hepatocellular carcinoma (HCC), sponsored by Hengrui Therapeutics. Started Nov 2016; status: completed.
02
Drugs
camrelizumab
03
Conditions
hepatocellular carcinoma (HCC)
Beyond the preview
Go deeper on CTR20160871.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20160871.